Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma

Silence Therapeutics announced that it will receive a $2M cash payment from Hansoh Pharmaceutical Group Company Limited following the achievement of a second undisclosed milestone related to the first target under the collaboration. “This represents an important milestone in our efforts to advance this program into the clinic with Hansoh,” said Craig Tooman, President and CEO of Silence. “This is an exciting time for Silence and our mRNAi GOLD platform as we continue to advance and expand our pipeline targeting a wide range of genetic diseases.”